Lawyer Profile Detail
AREA OF EXPERTISE
University of Ottawa
University of Western Ontario
David Tait is a partner in our Litigation Group in Toronto and joined the firm in 2006.
Mr. Tait focuses his practice on the resolution of intellectual property disputes (patents, trade-marks and copyright) and related commercial issues, by providing strategic advice and litigation services to a variety of clients.
With regard to patent law and patent litigation in Canada, Mr. Tait frequently represents innovative life sciences and pharmaceutical industry clients in patent infringement actions, PM(NOC) proceedings and Section 8 damages cases. He also provides strategic regulatory and litigation advice on medicines (Notice of Compliance), natural health products (Natural Health Product Licence) and Patented Medicines Prices Review Board issues.
Mr. Tait represents clients before the Federal Court, the Federal Court of Appeal and the Ontario Court.
As a part of the firm’s on-going commitment to pro bono activities, Mr. Tait also provides pro bono representation and performs other pro bono services including the assistance of child refugee claimants as designated representative before the Immigration and Refugee Board of Canada.
Mr. Tait is listed in the current edition of Intellectual Asset Management (IAM) Patent 1000 as a leading lawyer in the area of patent litigation.
Mr. Tait received his Master of Laws from the University of Ottawa where he prepared a thesis on the subject of software copyright infringement. Mr. Tait received his Bachelor of Laws from the University of Western Ontario where he graduated as a member of the Dean's Honours List and was the recipient of both the Law Society of Upper Canada Prize and the Carswell Prize. Mr. Tait also received his Bachelor of Science (Honours Chemistry) from the University of Waterloo and his Bachelor of Education from Queen's University.
Aside from his legal work, Mr. Tait plays rugby in the Toronto Rugby Union with three-time champions, the Bay Street RFC.
Canada's Federal Court of Appeal Upholds C$180 Million Judgment in Favour of Merck Against Apotex in a Landmark Patent Damages Ruling
Merck Awarded More Than $180 Million Against Apotex for Infringement of Lovastatin Patent
Pfizer Liable to Apotex for Section 8 Damages: Amount to Be Determined
The Federal Court of Appeal recently released an important decision on the doctrine of sound prediction (Eli Lilly Canada Inc. v. Apotex Inc. 2009 FCA 97)
Canadian Patent Office Rules on Requirements for an "Invention" for a Patent
Transactions & Cases
Federal Court awards Merck more than C$180 million in damages against Apotex for infringement of Lovastatin patent
Landmark patent infringement ruling by Federal Court on Merck's drug lovastatin
Abbott U.S. and Abbott Canada succeed in preventing launch of Generic BIAXIN XL in Canada